Trulicity vs Retatrutide Head-to-Head Efficacy: What the Data Actually Show

Why No Head-to-Head Trial Exists Yet

Comparing dulaglutide and retatrutide directly is not possible from a single trial because no randomized head-to-head study has been published. Retatrutide is still moving through phase 3 development. Any comparison right now is cross-trial, meaning differences in patient populations, baseline BMI, trial duration, and endpoint definitions all introduce uncertainty. Clinicians and patients should read the numbers below with that limitation in mind.

The Development Gap

Dulaglutide received FDA approval for type 2 diabetes in 2014 [1] and has accumulated nearly a decade of real-world prescribing data. Retatrutide completed a phase 2 trial reported in the New England Journal of Medicine in 2023 [2] and, as of mid-2025, remains without an FDA approval decision. That gap in regulatory history matters when weighing certainty of evidence.

Why Cross-Trial Numbers Still Inform Clinical Decisions

Cross-trial comparisons carry real limitations, but they are the standard tool clinicians use before outcomes trials finish. The FDA's own drug-approval process evaluates new agents against existing standard-of-care benchmarks. The American Diabetes Association's 2024 Standards of Care explicitly state that "selection of a glucose-lowering medication should be individualized based on efficacy, safety, cardiovascular and renal effects, and patient preferences" [3]. That framework requires comparing available evidence even when head-to-head data are absent.

Mechanism of Action: One Receptor vs. Three

How Dulaglutide Works

Dulaglutide is a selective GLP-1 receptor agonist. It mimics endogenous glucagon-like peptide-1, slowing gastric emptying, stimulating glucose-dependent insulin secretion, and suppressing glucagon release [4]. Its mechanism is well characterized across thousands of trial participants and years of post-marketing surveillance.

How Retatrutide Works

Retatrutide simultaneously activates three receptors: GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) [2]. The glucagon receptor component is the primary differentiator from dual agonists like tirzepatide. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation, which may partly explain the larger weight-loss signal seen in phase 2 [5]. The phrase "may explain" is deliberate here. Phase 3 mechanistic substudies are still ongoing.

Clinical Implication of the Mechanism Difference

More receptor targets does not automatically mean better outcomes for every patient. GLP-1 alone has generated class-wide cardiovascular benefit signals across multiple large outcome trials [6]. Whether adding GIP and glucagon receptor activity amplifies, preserves, or dilutes that cardiovascular signal for retatrutide is not yet known from prospective outcomes data.

Weight Loss Efficacy

This is where the evidence gap between the two drugs is most visible. The weight-loss numbers from retatrutide's phase 2 study are substantially larger than anything reported for dulaglutide across its clinical program.

Dulaglutide Weight-Loss Data

The AWARD program established dulaglutide's efficacy across several trials. In AWARD-11, participants with type 2 diabetes on 4.5 mg dulaglutide lost approximately 4.7 kg more than those on 1.5 mg over 36 weeks, but absolute weight loss at the highest approved dose remained modest relative to newer agents [7]. Dulaglutide was not designed or powered primarily as an obesity drug. The drug's label indication is glycemic control in type 2 diabetes, with a secondary cardiovascular risk-reduction indication added in 2020 [1].

Retatrutide Weight-Loss Data

In the Jastreboff et al. Phase 2 trial (N=338, 48 weeks), participants without type 2 diabetes who received retatrutide 12 mg lost a mean of 24.2% of body weight [2]. At the 8 mg dose, mean weight loss was 22.8%. The placebo group lost 2.1%. At 48 weeks, 26% of participants in the 12 mg group lost 30% or more of their baseline body weight. Those figures exceed anything in the published dulaglutide dataset by a wide margin.

To put the gap in concrete terms: a 100 kg person on dulaglutide might expect approximately 3 to 5 kg of weight loss over 9 months in a T2D population. The same person on retatrutide 12 mg, extrapolated from Jastreboff 2023, might expect roughly 24 kg. That extrapolation carries the caveat that the retatrutide trial enrolled people with obesity and without diabetes, a population known to show larger weight responses to GLP-1-class drugs than those with established T2D [2].

Phase 3 Retatrutide Obesity Data

Eli Lilly has disclosed phase 3 TRIUMPH program enrollment for retatrutide. As of the 2025 ADA Scientific Sessions, interim data suggested weight loss in the 20 to 25% range at 52 weeks in the obesity-focused arms, consistent with phase 2 signals [8]. Final phase 3 publications are expected in late 2025 or 2026.

Glycemic Efficacy

HbA1c Reduction: Dulaglutide

Across AWARD trials, dulaglutide 1.5 mg reduced HbA1c by a mean of 1.1 to 1.5 percentage points from baseline over 26 weeks in type 2 diabetes populations [7]. The higher 4.5 mg dose, approved in 2020, produced additional HbA1c reductions of roughly 0.2 to 0.4 percentage points compared to 1.5 mg [7]. These are clinically meaningful reductions and comparable to other established GLP-1 receptor agonists at similar dose levels.

HbA1c Reduction: Retatrutide

In the Jastreboff 2023 phase 2 trial, the enrolled population did not have type 2 diabetes, so direct HbA1c comparison data are not available from that publication [2]. A separate phase 2 trial in type 2 diabetes, reported at ADA 2023, showed retatrutide producing HbA1c reductions of approximately 2.0 percentage points at 24 weeks [9]. That signal is larger than dulaglutide's class-average HbA1c reduction, though it comes from an earlier-phase, shorter study with a smaller sample.

Fasting Glucose and Insulin Sensitivity

Both agents improve fasting plasma glucose through complementary but partially overlapping mechanisms. Dulaglutide's GLP-1 pathway drives glucose-dependent insulin secretion and suppresses postprandial glucagon [4]. Retatrutide's triple mechanism adds direct glucagon suppression via GCGR and the GIP-driven amplification of insulin secretion [5]. The additive effect of all three pathways may contribute to retatrutide's larger glycemic signal in T2D, but head-to-head T2D glycemic data are still phase 3 pending.

Cardiovascular Outcomes

REWIND: Dulaglutide's Proven Record

REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) enrolled 9,901 participants with type 2 diabetes and either established cardiovascular disease or multiple CV risk factors. Median follow-up was 5.4 years. Dulaglutide 1.5 mg weekly reduced the composite primary MACE endpoint (CV death, non-fatal MI, non-fatal stroke) by 12% compared to placebo (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) [6]. The absolute risk reduction was 1.4 percentage points. Non-fatal stroke drove most of the benefit in that decomposition.

The REWIND result established dulaglutide as an evidence-based choice in patients with T2D and elevated cardiovascular risk, alongside semaglutide (SUSTAIN-6) and liraglutide (LEADER) [10]. That level of evidence does not yet exist for retatrutide.

Retatrutide Cardiovascular Data

No dedicated cardiovascular outcome trial for retatrutide has been published. The FDA requires such trials for diabetes drugs in high-risk populations under the 2008 cardiovascular guidance, and Eli Lilly's TRIUMPH-CVOT trial is expected to begin reporting no earlier than 2027 [8]. The absence of CVOT data is not evidence of cardiovascular harm, but clinicians managing patients with established atherosclerotic cardiovascular disease should account for it.

The decision framework below reflects the current evidence gap:

Choose dulaglutide preferentially when:

• The patient has T2D with established ASCVD or high 10-year CV risk.
• A proven cardiovascular benefit endpoint is required for formulary or payer justification.
• The patient needs a drug with decade-long real-world safety data.
• Weight loss of 3 to 5 kg is clinically sufficient.

Consider retatrutide (once approved) preferentially when:

• The primary goal is substantial weight loss (15% or more of body weight).
• The patient has obesity with or without T2D and is not in a high-CV-risk category requiring a proven CVOT drug.
• Prior GLP-1 monotherapy produced suboptimal weight response.
• The patient and prescriber accept that phase 3 data will inform long-term safety more fully.

Safety and Tolerability

Shared GI Side Effects

Both agents share the GLP-1 class GI profile. Nausea, vomiting, and diarrhea are the most common adverse events and are typically dose-dependent and transient during uptitration [4]. In REWIND, 17.4% of dulaglutide participants reported nausea vs. 7.9% on placebo, with most events occurring in the first 2 to 4 weeks [6].

In Jastreboff 2023, nausea occurred in 42% of the retatrutide 12 mg group vs. 16% in placebo, and vomiting occurred in 25% vs. 7% [2]. The higher GI event rate in the retatrutide arm may reflect both its higher potency and the faster dose escalation used in phase 2. Phase 3 titration schedules are typically slower and may reduce this signal.

Hypoglycemia Risk

Dulaglutide carries low hypoglycemia risk as monotherapy because its insulin secretion is glucose-dependent [1]. In REWIND, severe hypoglycemia rates were 0.7 per 100 patient-years on dulaglutide vs. 0.6 on placebo in participants not on insulin or sulfonylureas [6]. Retatrutide's phase 2 T2D data suggest a similarly low monotherapy hypoglycemia rate, though the dataset is smaller [9].

Pancreatitis and Thyroid C-Cell Risk

The GLP-1 class carries an FDA-required warning for pancreatitis risk and thyroid C-cell tumor risk, based on rodent data and pharmacovigilance signals [1]. Dulaglutide's label contains this warning. Retatrutide's FDA label does not yet exist, but the mechanism overlap means it will almost certainly carry equivalent class warnings. Neither drug should be used in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 [1].

Renal and Hepatic Considerations

Dulaglutide does not require dose adjustment for renal impairment down to an eGFR of 15 mL/min/1.73m² [1]. Retatrutide's renal dosing guidance awaits an FDA label. Post-hoc REWIND subgroup analyses showed dulaglutide reduced the composite kidney outcome (new macroalbuminuria, sustained 40% eGFR decline, or renal replacement therapy) by 15% (HR 0.85, P=0.0004) [11], a clinically meaningful secondary finding.

Dosing, Administration, and Access

Dulaglutide Dosing

Dulaglutide is available as a prefilled single-dose pen in 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg strengths, injected subcutaneously once weekly [1]. The starting dose is 0.75 mg for patients sensitive to GI effects, escalating to 1.5 mg after 4 weeks. Further escalation to 3 mg and 4.5 mg is optional for additional glycemic effect. The pen device is widely regarded as patient-friendly with a hidden needle.

Retatrutide Dosing

The phase 2 Jastreboff trial used doses of 1 mg, 4 mg, 8 mg, and 12 mg, all once weekly, with gradual uptitration over 24 weeks before reaching target dose [2]. Phase 3 titration schedules have not been publicly finalized. Pen delivery is expected to mirror the format used for tirzepatide (Mounjaro/Zepbound), given Eli Lilly's manufacturing platform.

Cost and Insurance Coverage

Dulaglutide (Trulicity) has a list price of approximately $900 to $1,000 per month without insurance in the U.S. As of mid-2025, with manufacturer copay cards bringing out-of-pocket costs to $25 to $75 per month for commercially insured patients. Retatrutide has no commercial pricing as of this writing because it is not approved. Once approved, pricing will likely align with tirzepatide (Zepbound/Mounjaro), currently listed at $1,059 to $1,200 per month [12].

Summary Comparison Table

| Feature | Dulaglutide (Trulicity) | Retatrutide | |---|---|---| | Mechanism | GLP-1 agonist | GLP-1 / GIP / GCGR triple agonist | | FDA Status | Approved (T2D, CV risk reduction) | Phase 3, not approved | | Peak weight loss (trial) | ~4.7 kg additional vs. Lower dose (AWARD-11) | 24.2% mean body weight (Jastreboff 2023) | | HbA1c reduction | 1.1 to 1.5% (AWARD program) | ~2.0% in phase 2 T2D (24 weeks) | | CVOT data | REWIND: 12% MACE reduction | None published | | Dosing | 0.75 to 4.5 mg once weekly | 1 to 12 mg once weekly (phase 2) | | Common nausea rate | 17.4% (REWIND) | 42% at 12 mg (Jastreboff 2023) | | Renal dosing adjustment | Not required to eGFR 15 | Unknown (no approved label) |

What Clinicians Are Watching in 2025 and 2026

The most important data releases expected to sharpen this comparison include: full phase 3 TRIUMPH obesity results for retatrutide, the first retatrutide T2D phase 3 glycemic readout, and any interim CVOT safety data Eli Lilly discloses with the NDA submission. Physicians managing patients who are currently stable on dulaglutide and asking about switching should hold that conversation until the phase 3 efficacy and safety dataset is public and an FDA label exists with a formal indication, contraindication list, and dosing guidance [8].

The Endocrine Society's 2023 obesity pharmacotherapy clinical practice guideline states that "treatment decisions should be based on the totality of evidence, including efficacy, safety, tolerability, cost, and the individual patient's clinical profile," [13] a standard that currently favors dulaglutide in patients with high CV risk and favors awaiting retatrutide data for those whose primary goal is large-magnitude weight reduction.